Back Hepatitis C

Hepatitis C

Harvoni Coformulation Approved in Europe for Hepatitis C Genotypes 1 & 4

Gilead Sciences' Harvoni, a once-daily fixed-dose coformulation containing the nucleotide HCV polymerase inhibitor sofosbuvir and the NS5A replication complex inhibitor ledipasvir, has been approved by the European Commission for the treatment of people with hepatitis C genotypes 1 and 4, the company announced this week.

alt

AASLD 2014: Daclatasvir + Sofosbuvir Demonstrates Good Cure Rate for HCV Genotype 3 Patients

An all-oral combination of daclatasvir (Daklinza) plus sofosbuvir (Sovaldi) taken for 12 weeks produced sustained virological response rates of 90% for previously untreated patients and 86% for prior non-responders with hepatitis C virus genotype 3 in the Phase 3 ALLY-3 trial, researchers reported last week at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Boston. This regimen did not work as well, however, for people with liver cirrhosis.

alt

AASLD 2014: Sofosbuvir/Ledipasvir and AbbVie 3D Cure Most People with HCV Genotype 4

Sofosbuvir/ledipasvir (Harvoni) without ribavirin and AbbVie's 3D regimen (paritaprevir/ombitasvir plus dasabuvir) both produced high sustained virological response rates for patients with hepatitis C virus (HCV) genotype 4, according to a pair of studies presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston.

alt

AASLD 2014: Sofosbuvir + GS-5816 for 12 Weeks Shows High Cure Rates, 8 Weeks Less Effective

A 12-week oral combination of sofosbuvir plus the experimental NS5A inhibitor GS-5816 demonstrated high sustained virological response rates for people with difficult-to-treat HCV genotype 3 and other genotypes, according to Phase 2 study findings presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last week in Boston. Reducing treatment duration to 8 weeks resulted in lower efficacy for people with HCV genotypes 1 and 2, though genotype 3 patients still showed high response rates.

alt

AASLD 2014: Daclatasvir TRIO Regimen Has Good Cure Rates With or Without Cirrhosis

A 12-week oral regimen of daclatasvir, asunaprevir, and beclabuvir, with or without ribavirin, cured 86% to 90% of genotype 1 hepatitis C patients with cirrhosis in the Phase 3 UNITY-2 trial, while the TRIO regimen without ribavirin demonstrated similar sustained response rates for non-cirrhotics in UNITY-1, according to 2 late-breaking reports presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston. Findings suggest that ribavirin is still useful for some harder-to-treat patients.

alt

AASLD 2014: Grazoprevir/ Elbasvir Combo Shows High Cure Rates, Including Cirrhotics and Coinfected

An all-oral regimen of grazoprevir (MK-5172) and elbasvir (MK-8742), taken with or without ribavirin for 12 weeks, demonstrated high sustained virological response rates for treatment-naive and treatment-experienced genotype 1 hepatitis C patients, including people with liver cirrhosis and HIV/HCV coinfection, according to research presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston and published simultaeously in The Lancet. However, pushing treatment duration with this combination plus sofosbuvir down to 4 or 6 weeks raised the risk of treatment failure.

alt

AASLD 2014: Young Drug Injectors on Opioid Agonist Therapy Have Lower Risk of HCV Infection

Young people who inject drugs (PWID) who undergo opioid agonist maintenance therapy with methadone or buprenorphine have more than a 60% reduction in their risk of acquiring hepatitis C virus (HCV) over time, compared to those with no substance use treatment, according to a study presented Monday at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Boston. Findings were also published in the October 27 edition of JAMA Internal Medicine.

alt

AASLD 2014: Sofosbuvir/ Ledipasvir + Ribavirin Highly Effective for People with Decompensated Cirrhosis

An oral regimen of sofosbuvir/ledipasvir (Harvoni) plus ribavirin taken for 12 weeks cured most hepatitis C patients with decompensated cirrhosis, the most advanced stage of liver disease, according to a presentation at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston. Sustained response was associated with improved liver function in most patients.

alt

AASLD 2014: HIV Positive People Have High Survival Rates After Liver Transplants Due to HCC

People with HIV -- most of whom were coinfected with hepatitis B or C -- generally had good outcomes after liver transplantation due to hepatocellular carcinoma (HCC), with 5-year survival rates similar to those of HIV negative transplant recipients and better than those of people who underwent other types of liver cancer treatment, researchers reported at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston.

alt